OncoMatch/Clinical Trials/NCT06787664
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
Is NCT06787664 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies BL-B01D1 for chordoma.
Treatment: BL-B01D1 — This is an open-label, multicenter phase II study to evaluate the safety, efficacy and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with locally advanced or metastatic chordoma.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Chemotherapy, biological therapy, immunotherapy, etc. within 4 weeks or 5 half-lives before the first dose
Cannot have received: biological therapy
Chemotherapy, biological therapy, immunotherapy, etc. within 4 weeks or 5 half-lives before the first dose
Cannot have received: immunotherapy
Chemotherapy, biological therapy, immunotherapy, etc. within 4 weeks or 5 half-lives before the first dose
Cannot have received: small molecule targeted therapy
small molecule targeted therapy within 5 days
Cannot have received: palliative radiotherapy
palliative radiotherapy within 2 weeks
Lab requirements
Cardiac function
no severe cardiac dysfunction, left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify